|
1
|
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
|
Cancer Cell
|
2005
|
3.56
|
|
2
|
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
|
Proc Natl Acad Sci U S A
|
2005
|
1.30
|
|
3
|
Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms.
|
Radiat Res
|
2009
|
0.92
|
|
4
|
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1.
|
Bioorg Med Chem
|
2005
|
0.85
|
|
5
|
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.
|
Genes Cancer
|
2010
|
0.85
|
|
6
|
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity.
|
Bioorg Med Chem Lett
|
2004
|
0.83
|
|
7
|
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development.
|
Proc Natl Acad Sci U S A
|
2014
|
0.83
|
|
8
|
Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.
|
AAPS J
|
2012
|
0.82
|
|
9
|
Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.
|
Mol Cancer Ther
|
2014
|
0.80
|
|
10
|
Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy.
|
Pharm Res
|
2012
|
0.79
|
|
11
|
Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent.
|
Org Biomol Chem
|
2013
|
0.77
|
|
12
|
ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway.
|
PLoS One
|
2013
|
0.77
|
|
13
|
Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma.
|
Clin Cancer Res
|
2012
|
0.77
|
|
14
|
Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.
|
Invest New Drugs
|
2012
|
0.76
|
|
15
|
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.
|
J Pharm Biomed Anal
|
2011
|
0.75
|
|
16
|
Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS.
|
J Pharm Biomed Anal
|
2012
|
0.75
|